KYLYS is a Life Science Spin-off from the University of Geneva that has developed HA Pearls, a new type of biocompatible and biodegradable gel. These gels can be easily injected as a fluid gel at room temperature and have the ability to form microgel structures in the tissue at body temperature. This technology offers durable effects and prevents migration from the injection site. KYLYS aims to revolutionize the delivery of hyaluronic acid (HA) for medical, surgical, and aesthetic purposes, including in the fields of rheumatology, reconstructive surgery, drug delivery systems, and veterinary medicine. Their products have the potential to provide effective and safe solutions for tissue regeneration and aesthetic medicine.